Citations

Clear

65 citation(s) found for "Fox, Michael".

BRCA1, BRCA2 , and Associated Cancer Risks and Management for Male Patients
Shevach, Jeffrey , Castro, Elena , Couch, Fergus J. , Domchek, Susan M., Eeles, Rosalind A. , Lin, Daniel W., Morgan, Todd M. , Offit, Kenneth, Schaeffer, Edward M. , Szymaniak, Brittany M. , Eeles, Rosalind A , Morgan, Todd M , Cheng, Heather H. , Couch, Fergus J. , Giri, Veda N. , Hall, Michael J. , King, Mary‐Claire , Lin, Daniel W., Loeb, Stacy , Offit, Kenneth, Pritchard, Colin C. , Vassy, Jason L. , Katona, Bryson W , Maxwell, Kara N.

Mayo Clinic

JAMA Oncology | July 25, 2024 | Volume: 10 | Issue: 9 | Pages: 1272

10.1001/jamaoncol.2024.2185 | PMID 39052257 Get It

Importance Half of all carriers of inherited cancer-predisposing variants in BRCA1 and BRCA2 are male, but the implications for their health are underrecognized compared to female individuals. Germline variants in BRCA1 and BRCA2 (also known as pathogenic or likely pathogenic variants, referred to here as BRCA1/2 PVs) are well known to significantly increase the risk of breast and ovarian cancers in female carriers, and knowledge of BRCA1/2 PVs informs established cancer screening and options for risk reduction. While risks to male carriers of BRCA1/2 PVs are less characterized, there is convincing evidence of increased risk for prostate cancer, pancreatic cancer, and breast cancer in males. There has also been a rapid expansion of US Food and Drug Administration–approved targeted cancer therapies, including poly ADP ribose polymerase (PARP) inhibitors, for breast, pancreatic, and prostate cancers associated with BRCA1/2 PVs. Observations This narrative review summarized the data that inform cancer risks, targeted cancer therapy options, and guidelines for early cancer detection. It also highlighted areas of emerging research and clinical trial opportunities for male BRCA1/2 PV carriers. These developments, along with the continued relevance to family cancer risk and reproductive options, have informed changes to guideline recommendations for genetic testing and strengthened the case for increased genetic testing for males. Conclusions and Relevance Despite increasing clinical actionability for male carriers of BRCA1/2 PVs, far fewer males than female individuals undergo cancer genetic testing. Oncologists, internists, and primary care clinicians should be vigilant about offering appropriate genetic testing to males. Identifying more male carriers of BRCA1/2 PVs will maximize opportunities for cancer early detection, targeted risk management, and cancer treatment for males, along with facilitating opportunities for risk reduction and prevention in their family members, thereby decreasing the burden of hereditary cancer.
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Shah, Neil P. , Bhatia, Ravi , Altman, Jessica K. , Amaya, Maria L. , Begna, Kebede H. , Berman, Ellin , Clements, Joan , Collins, Robert H. , Curtin, Peter , Drazer, Michael W. , Maness, Lori J., Metheny, Leland , Moore, Joseph O., Oehler, Vivian G. , Pratz, Keith W. , Pusic, Iskra , Rose, Michal G., Shomali, William , Styler, Michael , Tanaka, Tiffany , Tantravahi, Srinivas K. , Thompson, James E. , Tsai, Steven , Vaughn, Jennifer E. , Welborn, Jeanna, Yang, David T. , Sundar, Hema, Gregory, Kristina M., Drazer, Michael , Bhatia, Ravi , Chan, Onyee , DeAngelo, Daniel J. , Mohan, Sanjay , Smith, B. Douglas , Talpaz, Moshe , Amaya, Maria

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 23, 2024 | Volume: 22 | Issue: 1 | Pages: 43-69

10.6004/jnccn.2024.0007 | PMID 38394770 Get It

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome resulting from a reciprocal translocation between chromosomes 9 and 22 [t9;22] that gives rise to a BCR::ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase in developed countries. Tyrosine kinase inhibitor (TKI) therapy is a highly effective treatment option for patients with chronic phase–CML. The primary goal of TKI therapy in patients with chronic phase–CML is to prevent disease progression to accelerated phase–CML or blast phase–CML. Discontinuation of TKI therapy with careful monitoring is feasible in selected patients. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with chronic phase–CML.
Feasibility and Safety of Multisite Tissue and Biofluid Sampling for Synuclein in Parkinson’s Disease: The Systemic Synuclein Sampling Study (S4) (P1.013)
Linder, Carly, Coffey, Christopher S. , Beach, Thomas G. , Riss, Holly, Ecklund, Dixie , Caspell‐Garcia, Chelsea , Dave, Kuldip D. , Deshpande, Sampada, Lasch, Shirley, Arnedo, Vanessa , Jennings, Danna , Mollenhauer, Brit , Foroud, Tatiana , Adler, Charles H. , Riley, Lindsey , Chahine, Lana M.

Mayo Clinic

Neurology | December 7, 2023 | Volume: 88 | Issue: 16_supplement | Pages: No page available

10.1212/wnl.88.16_supplement.p1.013 Get It

The BRIDGE Project (BRIDGing the Gap in StrokE Management): Trans-Atlantic Differences in Management of Carotid Stenosis (P07.250)
Balucani, Clotilde , Arnedo, Vanessa , Mas, Jean‐Louis , Brown, Martin M. , Gonzales, Nicole R. , Savitz, Sean I. , Brott, Thomas G. , Hacke, Werner , Leys, Didier , Grotta, James C. , Levine, Steven R.

Mayo Clinic

Neurology | December 7, 2023 | Volume: 80 | Issue: 7_supplement | Pages: No page available

10.1212/wnl.80.7_supplement.p07.250 Get It

Incidence of Parkinson Disease in North America (P1-1.Virtual)
Roberts, Eric , Eeden, Stephen Van Den, Savica, Rodolfo , Ross, Web, Marras, Connie , Tanner, Caroline M. , Ross, Webster G., Fiske, Brian , Beck, James C. , Willis, Allison W.

Mayo Clinic

Neurology | December 6, 2023 | Volume: 98 | Issue: 18_supplement | Pages: No page available

10.1212/wnl.98.18_supplement.2665 Get It

Germline BRCA testing in pancreatic cancer: improving awareness, timing, turnaround, and uptake
Golan, Talia , Casolino, Raffaella , Hammel, Pascal, Whitaker, Kristen , Hall, Michael J. , Riegert‐Johnson, Douglas L. , Riegert-Johnson, Douglas L, Biankin, Andrew V. , Hammel, Pascal

Mayo Clinic

Therapeutic Advances in Medical Oncology | September 15, 2023 | Volume: 15 | Issue: No issue available | Pages: No page available

10.1177/17588359231189127 | PMID 37720496 Get It

Prognosis is generally poor for patients with pancreatic ductal adenocarcinoma. However, patients with germline BRCA1 or BRCA2 mutations (gBRCAm) may benefit from first-line platinum-based chemotherapy and maintenance therapy with the poly(adenosine diphosphate-ribose) polymerase inhibitor olaparib following at least 16 weeks of first-line platinum-based chemotherapy without disease progression. Germline breast cancer gene (BRCA) testing is therefore important to ensure that patients receive the most effective treatment. In addition, testing for other DNA damage response gene mutations beyond gBRCAm may also guide treatment decisions. However, clinical pathways for genetic testing are often suboptimal, leading to delays in treatment initiation or missed opportunities for personalized therapy. Barriers to testing include low rates of referral and uptake, delays to referral and slow result turnaround times, cost, and biopsy and assay limitations if somatic testing is performed, leading to the requirement for subsequent dedicated germline testing. Low rates of referral may result from lack of awareness among physicians of the clinical value of testing, coupled with low confidence in interpreting test results and poor availability of genetic counseling services. Among patients, barriers to uptake may include similar lack of awareness of the clinical value of testing, anxiety regarding the implications of test results, lack of insurance coverage, fear of negative insurance implications, and socioeconomic factors. Potential solutions include innovative approaches to testing pathways, including ‘mainstreaming’ of testing in which BRCA tests are routinely arranged by the treating oncologist, with the involvement of genetic counselors if a patient is found to have a gBRCAm. More recently, the utility of multigene panel analyses has also been explored. Access to genetic counseling may also be improved through initiatives such as having a genetic counseling appointment for all new patient visits and telemedicine approaches, including the use of telephone consultations or DVD-assisted counseling. Educational programs will also be beneficial, and cost effectiveness is likely to improve as the number of targeted treatments increases and when the earlier detection of tumors in family members following cascade testing is considered.
American Football Play and Parkinson Disease Among Men
Bruce, Hannah J., Korell, Monica, Contreras, Brittany, Gottesman, Joshua , Kirsch, L. , Karim, Yasir, Martin, Brett, Palmisano, Joseph , Abdolmohammadi, Bobak , Nowinski, Chris, McKee, Ann C. , Alosco, Michael L. , Bruce, Hannah, Tripodis, Yorghos , McClean, Michael D , Tanner, Caroline M. , Shih, Ludy C. , Stein, Thor D. , Stern, Robert A. , Adler, Charles H. , Mez, Jesse

Mayo Clinic

JAMA Network Open | August 11, 2023 | Volume: 6 | Issue: 8 | Pages: e2328644

10.1001/jamanetworkopen.2023.28644 | PMID 37566412 Get It

ImportanceParkinsonism and Parkinson disease (PD) are known to result from repetitive head impacts from boxing. Repetitive head impacts from American football may also be associated with increased risk of neurodegenerative pathologies that cause parkinsonism, yet in vivo research on the association between football play and PD is scarce and limited by small samples and equivocal findings.ObjectiveTo evaluate the association between football participation and self-reported parkinsonism or PD diagnosis.Design, Setting, and ParticipantsThis cross-sectional study leveraged data from the online Fox Insight study. Participants completed online questionnaires and self-reported whether they currently had a diagnosis of Parkinson disease or parkinsonism by a physician or other health care professional. In November 2020, the Boston University Head Impact Exposure Assessment was launched for data collection on repetitive head impacts. Data used for this manuscript were obtained from the Fox Insight database on June 9, 2022. A total of 1875 men who endorsed playing any organized sport were included. Former athletes were divided into those who participated in football (n = 729 [38.9%]) and those who participated in other sports (reference group).ExposuresSelf-reported participation in football, duration and level of football play, age at first exposure.Main Outcomes and MeasuresLogistic regression tested associations between PD status and history of football play, duration of football play, highest level played, and age at first exposure, controlling for age, education, history of diabetes or heart disease, body mass index, history of traumatic brain injury with loss of consciousness, and family history of PD.ResultsIn this sample of 1875 men (mean [SD] age, 67.69 [9.84] years) enriched for parkinsonism or PD (n = 1602 [85.4%]), 729 (38.9%) played football (mean [SD] duration, 4.35 [2.91] years). History of playing football was associated with higher odds of having a parkinsonism or PD diagnosis (odds ratio [OR], 1.61; 95% CI, 1.19-2.17). Among the entire sample, longer duration of play was associated with higher odds of having a parkinsonism or PD diagnosis (OR, 1.12; 95% CI, 1.06-1.19). Among football players, longer duration of football play (OR, 1.12; 95% CI, 1.02-1.23) and higher level of play (OR, 2.93; 95% CI, 1.28-6.73) were associated with higher odds of having parkinsonism or PD.Conclusions and RelevanceIn this cross-sectional study of participants enriched for PD, participation in football was associated with higher odds of having a reported parkinsonism or PD diagnosis.
Osteochondral Lesions of the Ankle and Foot
Haug, Logan P. , Sill, Andrew , Kile, Todd A. , Fox, Michael G. , Shrestha, Roman , Sill, Andrew P., Shrestha, Roman, Patel, Karan A.

Mayo Clinic

Seminars in Musculoskeletal Radiology | May 25, 2023 | Volume: 27 | Issue: 03 | Pages: 269-282

10.1055/s-0043-1766110 | PMID 37230127 Get It

AbstractOsteochondral lesions (OCLs) in the ankle are more common than OCLs of the foot, but both share a similar imaging appearance. Knowledge of the various imaging modalities, as well as available surgical techniques, is important for radiologists. We discuss radiographs, ultrasonography, computed tomography, single-photon emission computed tomography/computed tomography, and magnetic resonance imaging to evaluate OCLs. In addition, various surgical techniques used to treat OCLs—debridement, retrograde drilling, microfracture, micronized cartilage-augmented microfracture, autografts, and allografts—are described with an emphasis on postoperative appearance following these techniques.